David Shumway

Dynport Vaccine Company, Llc

$6,214,596

Attributed

$6,214,596

Total exposure

Grants

Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).

Funding over time

peak $5.9M · FY2016–21

$10M$7.5M$5M$2.5M$0

'16

'17

'18

'19

'20

'21

Funding mix

By agency

NIH$6,214,596 · 2

By mechanism

N01$6,214,596 · 2

Top collaborators

No co-investigators on record.

Most similar at Dynport Vaccine Company, Llc

Same institution · by research overlap

Graig Shockey$9,887,057
Salama Balume$16,877,312
George Saviolakis$1,316,543
Casey Long$2,265,501
Preston Holley$300,000

Others in their field

Top investigators on “Communicable Diseases”

Jeffrey P Krischer · University Of South Florida$580,775,398
Judith S. Currier · University Of California Los Angeles$277,419,428
Michael David Hughes · Harvard University D/B/A Harvard School Of Public Health$240,302,862
Melynda Holmes · Technical Resources Inc$231,847,503
Lawrence Corey · Fred Hutchinson Cancer Center$228,424,910
Glenda E Gray · Wits Health Consortium (Pty), Ltd$227,738,417

Research focus

Communicable DiseasesPhase I Clinical TrialsNovel TherapeuticsInfectious Disease TreatmentInvestigationTherapeutic EvaluationTherapeutic AgentsMiddle East Respiratory Syndrome CoronavirusImmunoregulationClinical Trials UnitPhase I TrialImmunomodulatorsViralCoronavirusResource DevelopmentParasitic DiseasesPathogenNational Institute Of Allergy And Infectious DiseaseAntimicrobial ResistanceNeisseria GonorrhoeaeContractsBiodefenseDocumentationDevelopment Plans